2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemic
2013
Isoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2011
Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLOS ONE 2011, 6: e22927. PMID: 21829557, PMCID: PMC3146514, DOI: 10.1371/journal.pone.0022927.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIncident TB casesTB casesHIV prevalence countriesHigh HIV prevalence countriesPrevalence countriesHigh HIV prevalence areasRetreatment TB casesHIV prevalence areasIsoniazid-resistant tuberculosisControl of tuberculosisEffect of INHObserved time trendsWorld Health OrganizationPreventive therapyResistant tuberculosisIncident casesTreatment successPrevalence areasIsoniazid resistanceMultidrug resistanceHealth OrganizationTuberculosisINHNational data